Floatz logo

Panobinostat

Malignant Pleural Effusion

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Malignant Pleural Effusion cohort.

Asset / SponsorPhaseRating
Irinotecan
Peking University Cancer Hospital & Institute
Phase 3BB
Carboplatin
University of Washington
Phase 2BB
(+)-VINCRISTINE
Peking University Cancer Hospital & Institute
Phase 3BB
Inno-206
City of Hope Medical Center
Phase 2BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2BB

View all 27 →

Same molecule, other indications

Panobinostat is also rated in:

Hodgkins lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
Non-Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →